Canaccord raised the firm’s price target on Verve Therapeutics (VERV) to $32 from $29 and keeps a Buy rating on the shares. The firm said its 3Q24 earnings report was positive, with notable clinical progress made in both base editing programs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV: